Pharmacogenomics and functional gastrointestinal disorders

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Functional gastrointestinal disorders, including irritable bowel syndrome and functional dyspepsia, are highly prevalent disorders affecting approximately one in four people in Western societies. This article reviews examples of the role of pharmacogenomics in the safety and efficacy of medications used in the management of such disorders. These include variations in the effects of medications metabolized by cytochrome P450 enzymes (e.g., 2D6 and 2C19), and the effects of genetic polymorphisms in the promoter of the serotonin transporter protein, which influence the response to alosetron in patients with diarrhea-predominant irritable bowel syndrome. These observations suggest that pharmacogenomics will introduce a new era in pharmacotherapeutics in gastroenterology.

Original languageEnglish (US)
Pages (from-to)491-501
Number of pages11
JournalPharmacogenomics
Volume6
Issue number5
DOIs
StatePublished - Jul 2005

Fingerprint

Irritable Bowel Syndrome
Gastrointestinal Diseases
Pharmacogenetics
Cytochrome P-450 Enzyme System
Serotonin Plasma Membrane Transport Proteins
Dyspepsia
Genetic Polymorphisms
Gastroenterology
Diarrhea
Safety
Proteins
alosetron

Keywords

  • Alosetron
  • Codeine
  • CYP 450
  • Diarrhea
  • Dyspepsia
  • Gastroenterology
  • GNβ3
  • Irritable bowel syndrome
  • Nortryptiline
  • Serotonergic antagonist
  • SERT-P

ASJC Scopus subject areas

  • Genetics(clinical)
  • Pharmacology

Cite this

Pharmacogenomics and functional gastrointestinal disorders. / Camilleri, Michael.

In: Pharmacogenomics, Vol. 6, No. 5, 07.2005, p. 491-501.

Research output: Contribution to journalArticle

@article{77048ab4da4a4617a4304ebb42815bcd,
title = "Pharmacogenomics and functional gastrointestinal disorders",
abstract = "Functional gastrointestinal disorders, including irritable bowel syndrome and functional dyspepsia, are highly prevalent disorders affecting approximately one in four people in Western societies. This article reviews examples of the role of pharmacogenomics in the safety and efficacy of medications used in the management of such disorders. These include variations in the effects of medications metabolized by cytochrome P450 enzymes (e.g., 2D6 and 2C19), and the effects of genetic polymorphisms in the promoter of the serotonin transporter protein, which influence the response to alosetron in patients with diarrhea-predominant irritable bowel syndrome. These observations suggest that pharmacogenomics will introduce a new era in pharmacotherapeutics in gastroenterology.",
keywords = "Alosetron, Codeine, CYP 450, Diarrhea, Dyspepsia, Gastroenterology, GNβ3, Irritable bowel syndrome, Nortryptiline, Serotonergic antagonist, SERT-P",
author = "Michael Camilleri",
year = "2005",
month = "7",
doi = "10.2217/14622416.6.5.491",
language = "English (US)",
volume = "6",
pages = "491--501",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "5",

}

TY - JOUR

T1 - Pharmacogenomics and functional gastrointestinal disorders

AU - Camilleri, Michael

PY - 2005/7

Y1 - 2005/7

N2 - Functional gastrointestinal disorders, including irritable bowel syndrome and functional dyspepsia, are highly prevalent disorders affecting approximately one in four people in Western societies. This article reviews examples of the role of pharmacogenomics in the safety and efficacy of medications used in the management of such disorders. These include variations in the effects of medications metabolized by cytochrome P450 enzymes (e.g., 2D6 and 2C19), and the effects of genetic polymorphisms in the promoter of the serotonin transporter protein, which influence the response to alosetron in patients with diarrhea-predominant irritable bowel syndrome. These observations suggest that pharmacogenomics will introduce a new era in pharmacotherapeutics in gastroenterology.

AB - Functional gastrointestinal disorders, including irritable bowel syndrome and functional dyspepsia, are highly prevalent disorders affecting approximately one in four people in Western societies. This article reviews examples of the role of pharmacogenomics in the safety and efficacy of medications used in the management of such disorders. These include variations in the effects of medications metabolized by cytochrome P450 enzymes (e.g., 2D6 and 2C19), and the effects of genetic polymorphisms in the promoter of the serotonin transporter protein, which influence the response to alosetron in patients with diarrhea-predominant irritable bowel syndrome. These observations suggest that pharmacogenomics will introduce a new era in pharmacotherapeutics in gastroenterology.

KW - Alosetron

KW - Codeine

KW - CYP 450

KW - Diarrhea

KW - Dyspepsia

KW - Gastroenterology

KW - GNβ3

KW - Irritable bowel syndrome

KW - Nortryptiline

KW - Serotonergic antagonist

KW - SERT-P

UR - http://www.scopus.com/inward/record.url?scp=23044433707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23044433707&partnerID=8YFLogxK

U2 - 10.2217/14622416.6.5.491

DO - 10.2217/14622416.6.5.491

M3 - Article

C2 - 16013999

AN - SCOPUS:23044433707

VL - 6

SP - 491

EP - 501

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 5

ER -